Abstract
Carbapenem-resistant gram-negative organisms are a rising global concern, and novel therapeutic options are urgently needed. Cefepime/enmetazobactam (FEP/META), approved for the treatment of complicated urinary tract infections, could be an important asset in clinical care. This study aimed to determine the activity of FEP/META in a collection of genetically characterized carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa. FEP/META susceptibility was tested in 104 carbapenem-resistant clinical isolates (Escherichia coli, 14; Klebsiella pneumoniae, 30; other Enterobacterales [oEs]), 29; P. aeruginosa, 31) as tested by agar disk diffusion according to the European Committee on Antimicrobial Susceptibility Testing protocols. A carbapenemase gene was identified in 75% (78/104) of all isolates. A cefepime-resistant phenotype was detected in 89% (93/104) of all isolates. FEP/META was active against 29% (30/104) of all isolates tested, including 2 E. coli, 5 K. pneumoniae, 11 oEs, and 12 P. aeruginosa isolates. Twenty-two out of 78 (28%) of all carbapenemase-positive and 8 out of 26 (31%) of all carbapenemase-negative isolates were tested susceptible to FEP/META, respectively. META restored FEP susceptibility in 22/93 (24%) of cefepime-resistant isolates (16 carbapenemase-positive, 6 carbapenemase-negative), indicating a direct META effect to restore cefepime susceptibility. In conclusion, this study provides evidence for activity of FEP/META in selected carbapenem-resistant Enterobacterales and P. aeruginosa. Susceptibility varied across resistance genotypes and included isolates carrying resistance determinants formally not targeted by META. FEP/META could be an option for carbapenem-resistant organisms if other recommended therapies fail.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
